...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Comparative Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE
【24h】

Comparative Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE

机译：VX2和HCC细胞系对比较的化学敏感性在TACE中使用的药物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To compare the cytotoxic effects of 11 anticancer agents against VX2 and HepG2 cells in order to establish candidate drugs that can be tested preclinically on VX2 tumor model for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). Materials and Methods: VX2 and HepG2 cells were incubated with different drug concentrations. The half-maximal inhibitory concentration (IC50) values were determined by total cell protein assay for anthracyclines, platins, irinotecan, mytomicin-C (MMC), 5-fluorouracil (5-FU) and antiangiogenics. Results: IC50 values for VX2 and HepG2 were found close for doxorubicin (0.8 mu M vs. 1.1 mu M), MMC (13.9 mu M vs. 8.7 mu M), sunitinib (32.7 vs. 33.7 mu M), sorafenib (10.3 vs. 8.9 mu M), lapatinib (30 vs. 18.3 mu M) and different for platins and irinotecan. Oxaliplatin was less active against VX2 than HepG2 (IC50=41 mu M vs. 2.7 mu M), cisplatin was more active against VX2 than HepG2 (IC50=8.0 mu M vs. 15.9 mu M), whereas carboplatin had a low toxicity against both cell lines (70.4 mu M vs. 538.3 mu M). The toxicity of 5-FU against VX2 and HepG2 was low (IC50=560.6 mu M vs. 323.2 mu M). Irinotecan was less active against VX2 vs. HepG2 (IC50=44.5 mu M vs. 15.3 mu M). Bevacizumab had no effect on either of the cell lines up to 6.7 mu M. Conclusion: Drugs recommended for pre-clinical trials of TACE in the VX2 model are doxorubicin, sunitinib, sorafenib, MMC, lapatinib and 5-FU.
机译：目的：将11个抗癌剂对Vx2和HepG2细胞的细胞毒性效应进行比较，以建立候选药物，该药物可以在肝细胞癌（HCC）的ratratorial Chemoembolization（TACE）的VX2肿瘤模型上进行尿析药物。材料和方法：将Vx2和HepG2细胞与不同的药物浓度孵育。半最大抑制浓度（IC50）值由蒽环藻胺，铂，伊替锰，肌细胞蛋白-C（MMC），5-氟尿嘧啶（5-FU）和抗血管生物学的总细胞蛋白质测定法测定。结果：VX2和Hepg2的IC 50值接近多柔比星（0.8 mu m vs. 1.1 mu m），MMC（13.9 mu m vs. 8.7 mu m），孙尼替尼（32.7与33.7 mu m），索拉非尼（10.3 vs 。8.9 mu m），Lapatinib（30与18.3μm）和镀铂和伊立替康的不同。对Vx2的奥沙利铂的活性较小（IC50 =41μm，2.7μm），比vx2更活跃，而不是hepg2（Ic50 =8.0μm与15.9μm），而卡铂对两者的毒性很低细胞系（70.4μm与538.3μmm）。 5-FU对抗Vx2和HepG2的毒性低（IC50 =560.6μm，与323.2μm）。对VX2对抗Hep2（IC50 = 44.5 mu m vs.15.3 mu m），Irinotecan对Vx2较小。 Bevacizumab对中的任何一种细胞系都没有达到6.7 mu m的影响

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号